Enliven Therapeutics Inc.
$ 48.11
6.11%
17 Apr - close price
- Market Cap 2,876,998,000 USD
- Current Price $ 48.11
- High / Low $ 48.53 / 45.52
- Stock P/E N/A
- Book Value 7.73
- EPS -1.83
- Next Earning Report 2026-05-13
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.19 %
- ROE -0.27 %
- 52 Week High 48.53
- 52 Week Low 14.79
About
Enliven Therapeutics Inc. (Ticker: ELVN) is a pioneering biotechnology firm dedicated to revolutionizing cancer therapy and tackling other critical illnesses through its proprietary therapeutic platforms. The company boasts a robust pipeline of innovative drug candidates developed via advanced biopharmaceutical technologies aimed at improving patient outcomes and enhancing quality of life. With a strong emphasis on scientific innovation and a commitment to addressing significant unmet medical needs in oncology, Enliven is well-positioned to drive shareholder value and make meaningful contributions to the healthcare ecosystem.
Analyst Target Price
$51.29
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-12 | 2025-11-12 | 2025-08-13 | 2025-05-12 | 2025-03-12 | 2024-11-07 | 2024-08-13 | 2024-05-14 | 2024-03-14 | 2023-11-09 | 2023-08-10 | 2023-05-11 |
| Reported EPS | -0.48 | -0.32 | -0.49 | -0.57 | -0.46 | -0.4782 | -0.41 | -0.54 | -0.47 | -0.51 | -0.41 | -0.8 |
| Estimated EPS | -0.3778 | -0.5 | -0.55 | -0.5043 | -0.5175 | -0.5 | -0.55 | -0.57 | -0.54 | -0.47 | -0.36 | -0.63 |
| Surprise | -0.1022 | 0.18 | 0.06 | -0.0657 | 0.0575 | 0.0218 | 0.14 | 0.03 | 0.07 | -0.04 | -0.05 | -0.17 |
| Surprise Percentage | -27.0513% | 36% | 10.9091% | -13.028% | 11.1111% | 4.36% | 25.4545% | 5.2632% | 12.963% | -8.5106% | -13.8889% | -26.9841% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-13 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.44 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ELVN
2026-04-17 16:10:06
Enliven Therapeutics (ELVN) stock hit a new 52-week high of $46.83, reflecting a remarkable 194% year-to-date return, though InvestingPro data suggests it may be overvalued. The company's impressive stock performance is fueled by analyst bullishness, with price targets ranging from $39 to $60, and positive market sentiment influenced by Merck's recent acquisition of Terns Pharmaceuticals, which highlights strong demand in the oncology sector, particularly for chronic myeloid leukemia therapies.
2026-04-17 11:15:00
Enliven Therapeutics Inc. (NASDAQ:ELVN) has seen its stock price surge by 194% year-to-date, fueled by growing investor interest in the chronic myeloid leukemia (CML) treatment market. This rally follows Merck's $6.7 billion acquisition of Terns Pharmaceuticals, a competitor, which strengthened Merck's oncology pipeline with TERN-701, a CML treatment in clinical trials. Enliven Therapeutics is also developing its own CML treatment, ELVN-001, currently in early-stage studies, leading investment firms Mizuho and Clear Street to maintain "outperform" ratings and "buy" recommendations for ELVN shares.
2026-04-17 09:40:00
Enliven Therapeutics (ELVN) stock hit a new 52-week high of $46.83, demonstrating a significant 194% year-to-date return, though InvestingPro indicates it may be overvalued. The company's recent performance is bolstered by Merck's acquisition of Terns Pharmaceuticals, impacting the CML market and leading to raised price targets from analysts like H.C. Wainwright and Clear Street. Despite strong investor confidence, the company has not been profitable in the past twelve months.
2026-04-15 23:39:07
Enliven Therapeutics (NASDAQ:ELVN) experienced a 26.3% decrease in short interest in March, reducing to 6,053,456 shares, representing about 13.7% of the stock. Despite this, company insiders have been net sellers, offloading 37,460 shares worth approximately $1.04 million in the last 90 days, though insiders still own 25.9% of the company. Institutional ownership remains high at 95.08%, and the stock is trading near its 1-year high with a "Moderate Buy" consensus rating and a $43.40 price target.
2026-04-15 15:39:07
Enliven Therapeutics (NASDAQ: ELVN) is seeking shareholder approval to increase its authorized common stock from 100 million to 200 million shares at its 2026 virtual Annual Meeting on June 9, 2026. This proposal is intended to ensure sufficient shares for future issuances, though the board currently has no plans for immediate issuance. Shareholders will also vote on the election of two Class III directors, ratification of Deloitte & Touche LLP as the independent auditor, and advisory votes on executive compensation and the frequency of future Say-on-Pay votes.
2026-04-11 02:38:48
This article provides a detailed historical overview of ENLIVEN THERAPEUTICS INC (ELVN) quarterly earnings, including EPS and revenue actuals, analyst estimates, and surprise percentages. It highlights the company's past performance, upcoming earnings date, and beat rates. The data covers multiple fiscal quarters, offering insights into EPS and revenue growth trends and surprise distributions.
